CISH | OmnibusX

Name	Number of supported studies	Average coverage
regulatory T cell	8 studies	39% ± 25%	Explore
CD4-positive, alpha-beta T cell	5 studies	45% ± 21%	Explore
CD8-positive, alpha-beta T cell	4 studies	52% ± 19%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	4 studies	26% ± 5%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	4 studies	37% ± 26%	Explore
CD8-positive, alpha-beta memory T cell	3 studies	41% ± 30%	Explore
T cell	3 studies	19% ± 3%	Explore
type II pneumocyte	3 studies	26% ± 10%	Explore
effector CD4-positive, alpha-beta T cell	3 studies	50% ± 26%	Explore
effector memory CD4-positive, alpha-beta T cell	3 studies	44% ± 29%	Explore

sc-RNAseq data

Insufficient scRNA-seq data for expression of CISH at tissue level.

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
thymus	100%	4163.64	653 / 653	100%	37.08	603 / 605
kidney	100%	3762.38	89 / 89	97%	27.37	872 / 901
breast	100%	2517.01	458 / 459	96%	41.92	1074 / 1118
liver	99%	3049.81	224 / 226	91%	16.86	370 / 406
lung	100%	2950.28	577 / 578	88%	19.41	1018 / 1155
stomach	96%	799.55	345 / 359	91%	13.57	261 / 286
pancreas	98%	1151.11	321 / 328	89%	9.83	159 / 178
intestine	89%	831.26	863 / 966	91%	14.55	478 / 527
ovary	98%	1345.37	176 / 180	77%	9.66	329 / 430
uterus	89%	781.79	151 / 170	85%	11.17	388 / 459
bladder	81%	529.90	17 / 21	73%	9.76	370 / 504
prostate	91%	735.89	224 / 245	61%	5.03	304 / 502
esophagus	87%	659.06	1254 / 1445	61%	5.24	111 / 183
skin	76%	804.79	1372 / 1809	51%	4.44	240 / 472
spleen	100%	1040.85	241 / 241	0%	0	0 / 0
adrenal gland	72%	415.55	185 / 258	22%	4.16	50 / 230
adipose	93%	1504.48	1121 / 1204	0%	0	0 / 0
heart	87%	1245.95	753 / 861	0%	0	0 / 0
peripheral blood	87%	1197.04	812 / 929	0%	0	0 / 0
muscle	87%	2057.23	696 / 803	0%	0	0 / 0
tonsil	0%	0	0 / 0	84%	9.40	38 / 45
lymph node	0%	0	0 / 0	79%	10.92	23 / 29
blood vessel	69%	501.16	926 / 1335	0%	0	0 / 0
brain	6%	32.40	168 / 2642	14%	1.32	96 / 705
eye	0%	0	0 / 0	14%	0.91	11 / 80
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

GO_0016567	Biological process	protein ubiquitination
GO_0007205	Biological process	protein kinase C-activating G protein-coupled receptor signaling pathway
GO_0035556	Biological process	intracellular signal transduction
GO_0046854	Biological process	phosphatidylinositol phosphate biosynthetic process
GO_0001558	Biological process	regulation of cell growth
GO_0009968	Biological process	negative regulation of signal transduction
GO_0005942	Cellular component	phosphatidylinositol 3-kinase complex
GO_0005575	Cellular component	cellular_component
GO_0005829	Cellular component	cytosol
GO_0005886	Cellular component	plasma membrane
GO_0005515	Molecular function	protein binding
GO_0046935	Molecular function	1-phosphatidylinositol-3-kinase regulator activity
GO_0003674	Molecular function	molecular_function

Gene name	CISH
Protein name	Cytokine-inducible SH2-containing protein (CIS) (CIS-1) (Protein G18) (Suppressor of cytokine signaling) (SOCS)
Synonyms	G18
Description	FUNCTION: SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. CIS is involved in the negative regulation of cytokines that signal through the JAK-STAT5 pathway such as erythropoietin, prolactin and interleukin 3 (IL3) receptor. Inhibits STAT5 trans-activation by suppressing its tyrosine phosphorylation. May be a substrate-recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (By similarity). .
Accessions	ENST00000443053.6 [Q9NSE2-3] ENST00000348721.4 [Q9NSE2-1] Q9NSE2

CISH report